KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Assets (2016 - 2025)

Nektar Therapeutics has reported Return on Assets over the past 15 years, most recently at 0.53% for Q4 2025.

  • Quarterly results put Return on Assets at 0.53% for Q4 2025, down 15.0% from a year ago — trailing twelve months through Dec 2025 was 0.53% (down 15.0% YoY), and the annual figure for FY2025 was 0.53%, down 19.0%.
  • Return on Assets for Q4 2025 was 0.53% at Nektar Therapeutics, down from 0.45% in the prior quarter.
  • Over the last five years, Return on Assets for NKTR hit a ceiling of 0.33% in Q3 2024 and a floor of 0.65% in Q1 2023.
  • Median Return on Assets over the past 5 years was 0.45% (2025), compared with a mean of 0.34%.
  • Biggest five-year swings in Return on Assets: soared 95bps in 2024 and later plummeted -77bps in 2025.
  • Nektar Therapeutics' Return on Assets stood at 0.44% in 2021, then dropped by -12bps to 0.49% in 2022, then skyrocketed by 99bps to 0.0% in 2023, then tumbled by -13538bps to 0.39% in 2024, then crashed by -37bps to 0.53% in 2025.
  • The last three reported values for Return on Assets were 0.53% (Q4 2025), 0.45% (Q3 2025), and 0.5% (Q2 2025) per Business Quant data.